Novel targets for drug development

Join us in developing new therapeutic approaches for diseases with high unmet medical needs.
Apply for funding to promote your research and explore novel targets for drug development.

Submission ends August 31st, 2017

SUBMIT PROPOSAL

WHAT WE ARE FUNDING

We are offering grants for researchers investigating novel drug targets in the fields of Oncology, Gynecology, Cardiology and Hematology to promote innovative therapeutic ideas from basic research into novel drugs.
We provide financial support to test your hypothesis, start or extend your present research activities.

WHAT WE ARE FUNDING
YOUR BENEFITS
APPLICATION PROCESS
SUBMISSION

We are looking for novel targets for the indications of

Oncology, Gynecology, Cardiology and Hematology

Oncology

Focus on oncogenic signaling.

Gynecology

Focus on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna), uterine fibroids (uterine leiomyoma) and polycystic ovary syndrome (PCOS).

Focus on novel approaches to the care of chronic and/or acute pulmonary hypertension & adjacent lung indications, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and including kidney and lung diseases.

Hematology

Focus on novel, innovative targets for hemophilia.

- Target must be a nucleic acid or a protein (e.g. an enzyme, a receptor) whose activity can be modified by a drug

The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein.

- Target should have shown to be effective/ mechanistically involved in the disease by relevant in vitro or in vivo models.
- Target is disease-modifying and/or has a proven function in the pathophysiology of a disease.

YOUR BENEFITS

Financial Support

There are two types of grants, that will be allocated by Bayer depending on the target, the scientific data provided and the maturity of the proposal.

Support grants (€ 5,000 - €10,000)*
For druggable targets that are at a very early stage of discovery.

Focus grants (€ 10,000 - €125,000)*
For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.

* The size of the individual grant will depend on the target specifics and the phase of development and validation.

Conditions

- The decision on grant allocation is made at the sole and absolute discretion of Bayer.
- The applicant will retain ownership of any intellectual property he or she develops.
- Special conditions may apply for proprietary targets and the in-licensing of targets.

WHAT WE ARE FUNDING
YOUR BENEFITS
APPLICATION PROCESS
SUBMISSION

Grants may be complemented by

Within Bayer´s Compound Collection, we may have chemical probes to support your target validation efforts. Please indicate in your application which requirements potential tool compounds should fulfill.

Antibodies

Bayer's Antibody Discovery unit may be able to support your target validation work. Recombinant antibody engineering technology can be used to generate suitable antibodies for your validation needs.

Please specify which in vitro/in vivo models you´ll be using and the requirements potential tool antibodies should fulfill.

Technology platforms

We can offer access to different technologies to assist in your target validation, e.g. gene expression profiling or other state-of-the-art research technologies. Please detail your research interest for the technology platforms in the online submission.

Further Collaboration

Successful projects supported by the grant may lead to further collaboration.

WHAT WE ARE FUNDING
YOUR BENEFITS
APPLICATION PROCESS
SUBMISSION

APPLICATION PROCESS

1. CREATE AN ACCOUNT

? FAQ (/home/pharma/faq/index.php)
Contact Us (/scripts/components/forms/contact.php)

Pharmaceuticals

Grant applications can only be submitted via the online submission platform ScholarOne™. As first step, you'll have to create an account in the Grants4Targets Submission central.

2. SUBMIT YOUR TARGET IDEA

Deadline 31st of August 2017

You'll need to submit an abstract describing your idea and target, its characteristics and a separate description of its therapeutic potential.

Please note that only non-confidential information should be provided.

3. EVALUATION OF PROPOSALS

6 - 8 weeks after deadline

The information provided will be evaluated by Bayer scientific experts. The decision on amount of funding is dependent on the specific target and research plan proposed.

4. PROJECT STARTS

From November 2017

Successful applicants will be notified by Bayer and will receive further instructions concerning the grant. A Bayer caretaker will be in contact with you during the grant period.

READY, SET, SUBMIT

WHAT WE ARE FUNDING

YOUR BENEFITS

APPLICATION PROCESS

SUBMISSION

To submit, you will be redirected to ScholarOne™ online submission platform. All the information provided has to be non-confidential to allow a first evaluation of the proposal.

Please include the following information in your submission:

- Proposal abstract (max. 2000 characters)
  Describe your idea and target, its characteristics (indication and treatment paradigm, the target's druggability, and patent status).

Please indicate in the abstract if any particular data can only be disclosed under a Confidential Disclosure Agreement (CDA). In case your application is considered for further evaluation, we may contact you to discuss a CDA.

+ Description of therapeutic potential of the target

+ Upload CV and relevant publications

GO TO SUBMISSION

(http://mc.manuscriptcentral.com/grants4targets)

WORDS FROM OUT PARTNERS

PUBLICATIONS

- Gashaw I., et al., 2011. What makes a good drug target? (http://www.ncbi.nlm.nih.gov/pubmed?term=21945861)
- Kortylewicz Z., et al., 2012. Targeted molecular radiotherapy of cancer: Synthesis and Biological Evaluation (http://www.ncbi.nlm.nih.gov/pubmed/22339166)
- Lessl M., et al., 2011. Crowd sourcing in drug discovery (http://www.nature.com/nrd/journal/v10/n4/full/nrd3412.html)
- Stebbing J, et al., 2013. LMTK3 is implicated in endocrine resistance via multiple signaling pathways Oncogene (http://www.ncbi.nlm.nih.gov/pubmed/22869149)
- Suo G., et al., 2014. Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells. (http://www.ncbi.nlm.nih.gov/pubmed/24784716)
- Shahraz A., et al., 2015. Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages. (http://www.ncbi.nlm.nih.gov/pubmed/26582367)
- Dorsch H., et al., 2015, Grants4Targets: an open innovation initiative to foster drug discovery collaborations. (http://www.ncbi.nlm.nih.gov/pubmed/25430867)